These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 15065081)
1. Non-thiol farnesyltransferase inhibitors: utilization of the near aryl binding site by 5-arylacetylaminobenzophenones. Mitsch A; Böhm M; Sattler I; Schlitzer M Arch Pharm (Weinheim); 2004 Apr; 337(4):213-8. PubMed ID: 15065081 [TBL] [Abstract][Full Text] [Related]
2. Non-thiol farnesyltransferase inhibitors: utilization of the far aryl binding site by 5-cinnamoylaminobenzophenones. Mitsch A; Wissner P; Böhm M; Silber K; Klebe G; Sattler I; Schlitzer M Arch Pharm (Weinheim); 2004 Sep; 337(9):493-501. PubMed ID: 15362122 [TBL] [Abstract][Full Text] [Related]
3. Non-thiol farnesyltransferase inhibitors: utilization of the far aryl binding site by arylthienylacryloylaminobenzophenones. Mitsch A; Altenkämper M; Sattler I; Schlitzer M Arch Pharm (Weinheim); 2005 Jan; 338(1):9-17. PubMed ID: 15674808 [TBL] [Abstract][Full Text] [Related]
4. Non-thiol farnesyltransferase inhibitors: utilization of an aryl binding site by 5-arylacryloylaminobenzophenones. Mitsch A; Böhm M; Wissner P; Sattler I; Schlitzer M Bioorg Med Chem; 2002 Aug; 10(8):2657-62. PubMed ID: 12057654 [TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationships of novel anti-malarial agents part 8. Effect of different central aryls in biarylacryloylaminobenzophenones on antimalarial activity. Wiesner J; Mitsch A; Altenkämper M; Ortmann R; Jomaa H; Schlitzer M Pharmazie; 2003 Dec; 58(12):854-6. PubMed ID: 14703959 [TBL] [Abstract][Full Text] [Related]
15. Exploration of novel aryl binding sites of farnesyltransferase using molecular modeling and benzophenone-based farnesyltransferase inhibitors. Böhm M; Mitsch A; Wissner P; Sattler I; Schlitzer M J Med Chem; 2001 Sep; 44(19):3117-24. PubMed ID: 11543680 [TBL] [Abstract][Full Text] [Related]
16. Synthesis, molecular modeling, and structure-activity relationship of benzophenone-based CAAX-peptidomimetic farnesyltransferase inhibitors. Sakowski J; Böhm M; Sattler I; Dahse HM; Schlitzer M J Med Chem; 2001 Aug; 44(18):2886-99. PubMed ID: 11520197 [TBL] [Abstract][Full Text] [Related]
17. Development of benzophenone-based farnesyltransferase inhibitors as novel antimalarials. Kohring K; Wiesner J; Altenkämper M; Sakowski J; Silber K; Hillebrecht A; Haebel P; Dahse HM; Ortmann R; Jomaa H; Klebe G; Schlitzer M ChemMedChem; 2008 Aug; 3(8):1217-31. PubMed ID: 18470859 [TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of o-trifluoromethylbiphenyl substituted 2-amino-nicotinonitriles as inhibitors of farnesyltransferase. Wang GT; Wang X; Wang W; Hasvold LA; Sullivan G; Hutchins CW; O'Conner S; Gentiles R; Sowin T; Cohen J; Gu WZ; Zhang H; Rosenberg SH; Sham HL Bioorg Med Chem Lett; 2005 Jan; 15(1):153-8. PubMed ID: 15582430 [TBL] [Abstract][Full Text] [Related]
19. Non-thiol farnesyltransferase inhibitors: the concept of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors. Schlitzer M; Sattler I Eur J Med Chem; 2000; 35(7-8):721-6. PubMed ID: 10960188 [TBL] [Abstract][Full Text] [Related]
20. Non-peptidic, non-prenylic bisubstrate farnesyltransferase inhibitors. Part 3: structural requirements of the central moiety for farnesyltransferase inhibitory activity. Schlitzer M; Böhm M; Sattler I Bioorg Med Chem; 2000 Oct; 8(10):2399-406. PubMed ID: 11058034 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]